Steve Altman

Yembo is on a mission to build pioneering solutions to real world problems in the home services industry. From our start in the moving industry, to bringing our best-in-class AI product to the insurance industry, we’re on a mission to be the global leader in Artificial Intelligence (AI) enabled visual surveys for all home service organizations. We believe that cutting edge technology should be accessible to everyone. We’re committed to bringing digital transformation to the home services sector with the latest in AI technology, deep learning, computer vision, and robotics. We’re driven by 5 core values: 1. Make our customers lives easier - We delight our customers by understanding their needs, backing up our words with action 2. Collaborate effectively through teamwork - We have each others backs and collectively act for the good of the company with shared trust developed through thoughtful communication 3. Take ownership - We find undiscovered needs and opportunities for improvement and do what it takes to deliver 4. Deliver excellence by being 10x - We strive for outsized impact and effectiveness, are driven by clear goals and priorities, and let our results speak for themselves 5. Find fulfillment - We find happiness and satisfaction through providing value and purpose and always remember to have fun Team Yembotron is comprised of driven and passionate industry professionals that question the notion of ‘this is how it’s always been done’ every day. Are you the next 10x person to join our team, or know someone whod be a great fit? Check out yembo.ai/careers to learn more and connect with our team today.

Amionx is a leader in safe battery technology with headquarters in Carlsbad, CA. Amionx’s patented and proprietary Safe Core technology prevents batteries from being the source of explosion or fire without sacrificing the performance of the battery. This technology is transforming the current use of lithium-ion batteries and opening new market opportunities where lithium batteries would have been excluded primarily due to safety concerns. More information can be found on the Amionx website at www.amionx.com.

Brain Corp is the global leader in robotic AI software that powers the largest fleet of autonomous mobile robots (AMRs) operating in commercial public spaces. Global OEM partners use the companys cloud-connected platform, BrainOS®, to create scalable, self-driving robots that are used by end customers to clean floors and sense environmental data - turning manual operations into automated workflows. Fortune 500 brands across multiple verticals benefit from the growing portfolio of BrainOS®-powered robots and our industry-leading privacy, safety and efficiency tools that make managing and scaling automation easier. Brain Corp currently powers more than 35,000 AMRs, representing the largest fleet of its kind in the world.

CourseKey enables career colleges to boost revenue, maintain compliance, automate manual tasks, and drive career placement. Proudly supporting 200+ colleges training essential workers through modern, simple, and integrated software, CourseKey is the industry's leading education management platform.

About ViaCyte ViaCyte is a privately held regenerative medicine company developing novel cell replacement therapies as potential long-term diabetes treatments to achieve glucose control targets and reduce the risk of hypoglycemia and diabetes-related complications. ViaCyte’s product candidates are based on directed differentiation of pluripotent stem cells into PEC-01 pancreatic islet progenitor cells, which are then implanted in durable and retrievable cell delivery devices. ViaCyte demonstrated that when effectively engrafted, PEC-01 cells can mature into glucose-responsive insulin producing cells in patients with type 1 diabetes. To accelerate and expand its efforts, ViaCyte has established collaborative partnerships with leading companies including CRISPR Therapeutics and W.L. Gore & Associates. About ViaCyte’s Pipeline The PEC-Direct product candidate, currently being evaluated in the clinic, delivers ViaCyte’s PEC-01 cells (pancreatic islet progenitor cells) in a non-immunoprotective device and is being developed for type 1 diabetes patients who have hypoglycemia unawareness, extreme glycemic lability, and/or recurrent severe hypoglycemic episodes. The PEC-Encap (also known as VC-01) product candidate, also undergoing clinical evaluation, delivers the same pancreatic islet progenitor cells but in an immunoprotective device. PEC-Encap is being developed for all patients with type 1 diabetes. In collaboration with CRISPR Therapeutics, ViaCyte is developing immune-evasive stem cell lines from its proprietary CyT49 cell line. These immune-evasive stem cell lines, which are being used in the PEC-QT program, have the potential to further broaden the availability of cell therapy for all patients with insulin-requiring diabetes, type 1 and type 2. In addition, a pluripotent, immune evasive cell line has the potential to be used to produce any cell in the body, thus enabling many other potential indications.

Yembo is on a mission to build pioneering solutions to real world problems in the home services industry. From our start in the moving industry, to bringing our best-in-class AI product to the insurance industry, we’re on a mission to be the global leader in Artificial Intelligence (AI) enabled visual surveys for all home service organizations. We believe that cutting edge technology should be accessible to everyone. We’re committed to bringing digital transformation to the home services sector with the latest in AI technology, deep learning, computer vision, and robotics. We’re driven by 5 core values: 1. Make our customers lives easier - We delight our customers by understanding their needs, backing up our words with action 2. Collaborate effectively through teamwork - We have each others backs and collectively act for the good of the company with shared trust developed through thoughtful communication 3. Take ownership - We find undiscovered needs and opportunities for improvement and do what it takes to deliver 4. Deliver excellence by being 10x - We strive for outsized impact and effectiveness, are driven by clear goals and priorities, and let our results speak for themselves 5. Find fulfillment - We find happiness and satisfaction through providing value and purpose and always remember to have fun Team Yembotron is comprised of driven and passionate industry professionals that question the notion of ‘this is how it’s always been done’ every day. Are you the next 10x person to join our team, or know someone whod be a great fit? Check out yembo.ai/careers to learn more and connect with our team today.

Amionx is a leader in safe battery technology with headquarters in Carlsbad, CA. Amionx’s patented and proprietary Safe Core technology prevents batteries from being the source of explosion or fire without sacrificing the performance of the battery. This technology is transforming the current use of lithium-ion batteries and opening new market opportunities where lithium batteries would have been excluded primarily due to safety concerns. More information can be found on the Amionx website at www.amionx.com.

Brain Corp is the global leader in robotic AI software that powers the largest fleet of autonomous mobile robots (AMRs) operating in commercial public spaces. Global OEM partners use the companys cloud-connected platform, BrainOS®, to create scalable, self-driving robots that are used by end customers to clean floors and sense environmental data - turning manual operations into automated workflows. Fortune 500 brands across multiple verticals benefit from the growing portfolio of BrainOS®-powered robots and our industry-leading privacy, safety and efficiency tools that make managing and scaling automation easier. Brain Corp currently powers more than 35,000 AMRs, representing the largest fleet of its kind in the world.

CourseKey enables career colleges to boost revenue, maintain compliance, automate manual tasks, and drive career placement. Proudly supporting 200+ colleges training essential workers through modern, simple, and integrated software, CourseKey is the industry's leading education management platform.

About ViaCyte ViaCyte is a privately held regenerative medicine company developing novel cell replacement therapies as potential long-term diabetes treatments to achieve glucose control targets and reduce the risk of hypoglycemia and diabetes-related complications. ViaCyte’s product candidates are based on directed differentiation of pluripotent stem cells into PEC-01 pancreatic islet progenitor cells, which are then implanted in durable and retrievable cell delivery devices. ViaCyte demonstrated that when effectively engrafted, PEC-01 cells can mature into glucose-responsive insulin producing cells in patients with type 1 diabetes. To accelerate and expand its efforts, ViaCyte has established collaborative partnerships with leading companies including CRISPR Therapeutics and W.L. Gore & Associates. About ViaCyte’s Pipeline The PEC-Direct product candidate, currently being evaluated in the clinic, delivers ViaCyte’s PEC-01 cells (pancreatic islet progenitor cells) in a non-immunoprotective device and is being developed for type 1 diabetes patients who have hypoglycemia unawareness, extreme glycemic lability, and/or recurrent severe hypoglycemic episodes. The PEC-Encap (also known as VC-01) product candidate, also undergoing clinical evaluation, delivers the same pancreatic islet progenitor cells but in an immunoprotective device. PEC-Encap is being developed for all patients with type 1 diabetes. In collaboration with CRISPR Therapeutics, ViaCyte is developing immune-evasive stem cell lines from its proprietary CyT49 cell line. These immune-evasive stem cell lines, which are being used in the PEC-QT program, have the potential to further broaden the availability of cell therapy for all patients with insulin-requiring diabetes, type 1 and type 2. In addition, a pluripotent, immune evasive cell line has the potential to be used to produce any cell in the body, thus enabling many other potential indications.